OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3yadChG
via IFTTT